Factor H Antibody (Polyclonal)

A goat antiserum raised against human Factor H.


Product Specifications

Citations 32
Clonality

Polyclonal

Immunogen Highly purified human Factor H
Applications See citations and technical data sheet for application info.
Concentration > 40 mg/mL
Conjugate Unconjugated
Cross Reactivity

Human, Baboon, Horse, Dog, Cat, Rabbit, Hamster, Mouse, Rat, Guinea Pig

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog Number A312
Catalog Number (CE) N/A
Size 2.0 mL
Price (USD) $195.00
Price (EURO) 170,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A goat antiserum raised against human Factor H.

Size 2.0 mL
Concentration

> 40 mg/mL

Applications See citations and technical data sheet for application info.
Form Liquid. Whole Antiserum. ≤ 0.1% Sodium Azide
Clonality Polyclonal
Immunogen Highly purified human Factor H
Conjugate Unconjugated
Cross Reactivity Human, Baboon, Horse, Dog, Cat, Rabbit, Hamster, Mouse, Rat, Guinea Pig
Isotype Goat IgG
Purity N/A
Source

Goat

Specificity The Anti-human Factor H polyclonal antisera was tested against normal human serum/plasma by immunodiffusion, one-dimensional immunoelectrophoresis, and rocket immunoelectrophoresis. The antisera was determined to be monospecific for Factor H at varying concentrations.
Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

Factor H is a single-chain glycoprotein with a molecular weight of approximately 150 KD. The concentration of this protein in normal human plasma/serum is approximately 500 µg/mL. Factor H can regulate the complement system on both the cellular surface and in fluid phase, and plays roles in both the alternative and classical pathways of activation. Factor H regulates formation and function of C3 convertase enzyme in the alternative pathway. It binds to C3b and inhibits C3 convertase formation, dissociates assembled C3 convertase, accelerates Factor I mediated cleavage of C3b to C3bi, and hinders C5 binding to the C3b subcomponent of both the alternative and classical pathways. Factor H also regulates the spontaneous fluid-phase activation of the alternative complement pathway by C3b-like forms of C3 that continuously arise in plasma and serum. Therefore, when concentrations of Factor H fall below normal levels, rapid fluid-phase activation occurs which causes consumption of complement components both in vivo and in vitro.

Citations

Title Year Applications Sample Species Sample Sample Details

Recruitment of Factor H to the Streptococcus suis Cell Surface is Multifactorial.

2016

ELISA

Bacteria

Streptococcus suis

Antigenic Variation in Streptococcus pneumoniae PspC Promotes Immune Escape in the Presence of Variant-Specific Immunity.

2018

FC

Bacteria

Streptococcus pneumoniae

Mechanism of Borrelia immune evasion by FhbA-related proteins

2022

WB

Bacteria

Borrelia hermsii

Reduction of complement factor H binding to CLL cells improves the induction of rituximab-mediated complement-dependent cytotoxicity

2013

WB

Cell Culture

CLL Cells

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

2019

ELISA

Human

Plasma

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

2019

ELISA

Human

Serum

Defining the Glycosaminoglycan Interactions of Complement Factor H-Related Protein 5

2021

ELISA

Human

Purified protein

Common haplotypes at the CFH locus and low-frequency variants in CFHR2 and CFHR5 associate with systemic FHR concentrations and age-related macular degeneration.

2021

ELISA

Human

Serum

Age-Related Macular Degeneration

Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene.

2021

ELISA

Human

Plasma

Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation.

2021

ELISA

Human

Protein

Factor H WT and Variants

The C-type lectin of the aggrecan G3 domain activates complement

2013

ELISA

Human

Purified protein

Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD

2016

ELISA

Human

Purified Protein

Mapping rare, deleterious mutations in Factor H: Association with early onset, drusen burden, and lower antigenic levels in familial AMD

2016

ELISA

Human

Serum

Cyclosporine induces endothelial cell release of complement-activating microparticles

2013

FC

Human

Endothelial Cells

Microparticles incubation

Immune evasion by acquisition of complement inhibitors: the mould Aspergillus binds both factor H and C4b binding protein

2008

FC, IF

Human

Plasma

Aspergillus incubated

Anti-Factor H Antibody Reactivity in Young Adults Vaccinated With a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.

2019

Hemolytic Assay

Human

Serum

ApoE Attenuates Unresolvable Inflammation by Complex Formation With Activated C1q.

2019

IF

Human

Choroid plexus Tissue

Complement Factor H Expressed by Retinal Pigment Epithelium Cells Can Suppress Neovascularization of Human Umbilical Vein Endothelial Cells: An in vitro Study

2015

IF, WB

Human

ARPE-19 cells

Activation of complement system in kidney after ketoprofen-induced kidney injury in sheep

2015

IHC

Human

Kidney Tissue

Attenuation of renal ischemia and reperfusion injury by human adrenomedullin and its binding protein

2010

WB

Human

Plasma

Resuscitation of uncontrolled traumatic hemorrhage induced by severe liver injury: the use of human adrenomedullin and adrenomedullin binding protein-1

2010

WB

Human

Plasma

Expression of complement components, receptors and regulators by human dendritic cells

2011

WB

Human

Monocyte Derived Dendritic Cell

Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.

2020

ELISA, IF, WB

Mouse

Kidney Tissue

Circulating FH Protects Kidneys From Tubular Injury During Systemic Hemolysis.

2020

ELISA, IF, WB

Mouse

Plasma

Annexin A2 Enhances Complement Activation by Inhibiting Factor H

2016

ELISA, WB

Mouse

Kidney Tissue

Annexin A2 Enhances Complement Activation by Inhibiting Factor H

2016

ELISA, WB

Mouse

Plasma

Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase.

2009

WB

Mouse

Serum

Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury

2011

WB

Mouse

Serum

Regulation of C3 Activation by the Alternative Complement Pathway in the Mouse Retina

2016

WB

Mouse

Plasma

Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation

2009

ELISA

N/A

Purified protein

SLRP

Pro-inflammatory cytokines from Kupffer cells downregulate hepatocyte expression of adrenomedullin binding protein-1

2007

WB

Rat

Hepatocytes

Pro-inflammatory cytokines from Kupffer cells downregulate hepatocyte expression of adrenomedullin binding protein-1

2007

WB

Rat

Kupffer cells